AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

About this update from Aim Immunotech Inc.

[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ExfZBbISk6KxGeFYkBNhew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"AIM CEO Thomas K. Equels","length":24,"tagName":"p"},{"type":"image","alt":"AIM CEO Thomas K. Equels","displaySize":"","headline":null,"caption":"AIM CEO Thomas K. Equels","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1169,"height":2046,"url":"https://media.zenfs.com/en/globenewswire.com/58da3457eebd71d3b4d11d10eae928f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.ylkXjHXD1JR9p3g93HzIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/58da3457eebd71d3b4d11d10eae928f6","width":960,"height":1680},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/y45DAQiwjdbckl3a28Y0CA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzMzg7aD00MDkyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/58da3457eebd71d3b4d11d10eae928f6","width":1169,"height":2046}}},{"type":"text","content":"Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here","length":236,"tagName":"p"},{"type":"text","content":"Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program","length":159,"tagName":"p"},{"type":"text","content":"OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland.","length":399,"tagName":"p"},{"type":"text","content...

More updates from Aim Immunotech Inc.